#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Nephrotic syndrome Depression Congenital absence of bile ducts Deafness Oesophageal achalasia Malignant fibrous histiocytoma Meningitis meningococcal Pleomorphic liposarcoma Renal cancer metastatic Meningococcal immunisation Ewing's sarcoma recurrent Tuberous sclerosis complex Cytomegalovirus infection Fragile X syndrome Synovial sarcoma metastatic More trials…

    Learn about Rare Diseases

    Hyperoxaluria – Diagnostics Burkitt’s lymphoma – Treatment Tuberous sclerosis complex – Diagnostics Primary biliary cholangitis – Diagnostics Hepatoblastoma – Treatment IgA nephropathy – Trials in Disease Pulmonary sarcoidosis – Life with Disease Systemic mastocytosis – Basic Information Uterine leiomyosarcoma – Life with Disease Hereditary angioedema – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gs-1427 Clioquinol Serpina1(Human)-Aav8-1 Regn7508 Alnuctamab Azd0901 Travoprost AMMONIUM (15N) CHLORIDE Nvdx3 Abc-31-116 [18F]Mc225 Estriol Etravirine Buclizine Hydrochloride HYDROXYCHLOROQUINE Dostarlimab Hmb-001 Crinecerfont Methylone Nifedipine More therapies…

    Learn about Your Condition

    Vascular malformation Colon cancer stage II Femoral neck fracture Diabetes insipidus Neuralgia Pulmonary sarcoidosis Von Hippel-Lindau disease Demyelination Vertigo Spinal pain Sarcoma Breast cancer stage IV Non-obstructive cardiomyopathy Osteonecrosis of jaw Carpal tunnel syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Asklepios Kliniken Hamburg GmbH

Asklepios Kliniken Hamburg GmbH

Eissendorfer Pferdeweg 52, Heimfeld, Hamburg, 21075, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Talquetamab, Daratumumab, and Pomalidomide with Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Daratumumab
    • Dexamethasone
    • Dexamethasone Ph. Eur.
    Belgium Czechia France Germany Greece Italy +3

  • Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Bortezomib
    • Carfilzomib
    • Dexamethasone
    Austria Belgium Czechia Denmark France Germany +7

  • Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

    Not recruiting

    3 1
    Investigated Drugs:
    • Asundexian
    Austria Belgium Bulgaria Czechia Denmark Finland +14

  • Study of Pembrolizumab with Chemotherapy for Patients with Resectable Stage II, IIIA, and IIIB Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Cisplatin
    • Gemcitabine
    • Pembrolizumab
    Belgium Estonia France Germany Ireland Italy +5

  • Study on Budesonide Tablets for Preventing Esophageal Narrowing in Adults After Cancer Tissue Removal

    Not recruiting

    2 1
    Investigated Diseases:
    • Oesophageal adenocarcinoma
    • Oesophageal squamous cell carcinoma
    • Barrett’s oesophagus
    Investigated Drugs:
    • Budesonide
    France Germany The Netherlands Poland Portugal Spain +1

  • Study of Zipalertinib with Chemotherapy vs. Chemotherapy Alone for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Pemetrexed
    Belgium Bulgaria France Germany Greece Italy +4

  • Study of Volrustomig with Carboplatin and Pemetrexed for Patients with Unresectable Pleural Mesothelioma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Pleural mesothelioma
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Infliximab
    Belgium Denmark France Germany Italy The Netherlands +3

  • Study of Pembrolizumab and Axitinib Combination Versus Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic renal cell carcinoma
    Investigated Drugs:
    • Axitinib
    • Pembrolizumab
    • Sunitinib
    Czechia France Germany Hungary Ireland Poland +1

  • Study of Pembrolizumab, Trastuzumab, and Chemotherapy for Patients with HER2 Positive Advanced Stomach or Gastroesophageal Junction Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Adenocarcinoma gastric
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Capecitabine
    • Cisplatin
    • Fluorouracil
    France Germany Ireland Italy Poland Spain

  • Study of Tislelizumab, Dacarbazine, Vinblastine Sulfate, and Doxorubicin Hydrochloride for Adults with Early-Stage Unfavorable Hodgkin Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Dacarbazine
    • Doxorubicin
    • Tislelizumab
    Germany
Previous Page
1 … 9 10 11 12 13
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!